Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Current management of relapsing-remitting multiple sclerosis.

Sedal L, Wilson IB, McDonald EA.

Intern Med J. 2014 Oct;44(10):950-7. doi: 10.1111/imj.12558.

PMID:
25302718
2.

Seizures during high-dose antidepressant therapy: a case series with clinical and video-electroencephalography characteristics.

Ducharlet K, Seneviratne U, Sedal L, Salzberg M, Cook M, D'Souza W.

Intern Med J. 2013 Sep;43(9):1039-42. doi: 10.1111/imj.12239.

PMID:
24004394
3.

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group.

Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x.

PMID:
20561039
4.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group.

N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

5.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.

PMID:
19815268
6.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
7.

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group.

Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28.

PMID:
18755819
8.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
9.

The cost of multiple sclerosis in Australia.

Taylor B, McDonald E, Fantino B, Sedal L, MacDonnell R, Pittas F, Groom T, Beresniak A.

J Clin Neurosci. 2007 Jun;14(6):532-9. Erratum in: J Clin Neurosci. 2008 Oct;15(10):1189. Beresniak, Ariel [added].

PMID:
17430777
10.

Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.

Chapman C, Tubridy N, Cook MJ, Mitchell PJ, MacGregor LR, Lovelock C, Litewka L, Sedal L, Kilpatrick TJ, Butzkueven H.

J Clin Neurosci. 2006 Jul;13(6):636-8. Epub 2006 Jun 21.

PMID:
16790352
11.

Subjective complaints, verbal fluency, and working memory in mild multiple sclerosis.

Matotek K, Saling MM, Gates P, Sedal L.

Appl Neuropsychol. 2001;8(4):204-10.

PMID:
11989723
12.

The limitations of immunosuppressant therapy in Multiple Sclerosis.

Sedal L.

J Clin Neurosci. 2000 Nov;7(6):563-4; discussion 564-5. No abstract available.

PMID:
11029245
13.
14.
15.

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome.

Pellegrini M, O'Brien TJ, Hoy J, Sedal L.

Acta Neurol Scand. 1996 Feb-Mar;93(2-3):203-6. Review.

PMID:
8741144
16.

Neurological observations.

Sedal L.

Aust Fam Physician. 1995 Oct;24(10):1843-5, 1848-9.

PMID:
8546611
17.

Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology.

Polihronis M, Paizis K, Carter G, Sedal L, Murphy B.

J Neurol Sci. 1993 Apr;115(2):230-3.

PMID:
8387101
18.

Influence of fatty acid content of lysophosphatidyl choline on its myelinotoxic properties.

Sedal L, Jennings KH, Allt G, Ghabriel MN, Harrison MJ.

Eur Neurol. 1992;32(1):4-10.

PMID:
1563454
19.

Focal cerebral ischaemia induced by postural change.

Sedal L, Heywood J.

Clin Exp Neurol. 1989;26:229-35.

PMID:
2642134
20.

A family with late onset autosomal dominant cerebellar degeneration.

Collins S, Sedal L, King J, Donaldson I.

Clin Exp Neurol. 1988;25:61-5.

PMID:
3267486
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk